HAYWARD, Calif., Jan. 16, 2018 /PRNewswire/ -- Impax
Laboratories, Inc. (NASDAQ: IPXL) announced today that the
Company will release its fourth quarter and full year 2017
financial results on Thursday, March 1,
2018, prior to the open of the U.S. financial markets. The
Company will host a conference call and live webcast with the
investment community at 8:30 a.m., Eastern
Time on March 1,
2018.
The financial results and live webcast will be accessible
through the Investor Relations section of the Company's Web site at
http://investors.impaxlabs.com.
To access the call through a conference line, dial (877)
356-3814 (in the U.S.) and (706) 758-0033 (international callers).
The conference ID is 7677287.
A replay of the conference call will be available for seven days
shortly after the call. To access the replay, dial (855) 859-2056
(in the U.S.) and (404) 537-3406 (international callers). The
access code for the replay is 7677287.
About Impax Laboratories, Inc.
Impax Laboratories,
Inc. (Impax) is a specialty pharmaceutical company applying its
formulation expertise and drug delivery technology to the
development of controlled-release and specialty generics in
addition to the development of central nervous system disorder
branded products. Impax markets its generic products through its
Impax Generics division and markets its branded products through
the Impax Specialty Pharma division. Additionally, where
strategically appropriate, Impax develops marketing partnerships to
fully leverage its technology platform and pursues partnership
opportunities that offer alternative dosage form technologies, such
as injectables, nasal sprays, inhalers, patches, creams, and
ointments.
For more information, visit Impax's website at:
www.impaxlabs.com.
Contact:
Mark
Donohue
Investor Relations and Corporate Communications
(215)
558-4526
www.impaxlabs.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/impax-to-report-fourth-quarter-and-full-year-2017-results-on-march-1-2018-300582839.html
SOURCE Impax Laboratories, Inc.